First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study.

BACKGROUND: The targeted therapy cetuximab [directed at the epidermal growth factor receptor (EGFR)] in combination with 5-fluorouracil and platinum-based chemotherapy (the EXTREME regimen) has shown substantial efficacy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Thus, this scheme has been established as the preferred first-line option for these patients. However, more recently, a new strategy combining platinum, taxanes, and cetuximab (the TPEx regimen) has demonstrated similar efficacy with a more favorable toxicity profile in clinical trials. AIM: To evaluate the safety and efficacy of the TPEx scheme as first-line therapy in advanced SCCHN in a multicenter cohort study. METHODS: This retrospective multicenter cohort study included patients with histologically confirmed recurrent or metastatic SCCHN treated with first-line TPEx at five medical centers in Argentina between January 1, 2017 and April 31, 2020. Chemotherapy consisted of four cycles of docetaxel, cisplatin, and cetuximab followed by cetuximab maintenance therapy. Clinical outcomes and toxicity profiles were collected from medical charts. Treatment response was assessed by the investigator in accordance with Response Evaluation Criteria in Solid Tumors (version 1.1). Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0). RESULTS: Twenty-four patients were included. The median age at diagnosis was 58 years (range: 36-77 years). The majority of patients (83.3%) received at least four chemotherapy cycles in the initial phase. In the included group, the overall response rate was 62.5%, and 3 patients achieved a complete response (12.5%). The median time to response was 2.4 mo [95% confidence interval (CI): 1.3-3.5]. With a median follow-up of 12.7 mo (95%CI: 8.8-16.6), the median progression-free survival (PFS) was 6.9 mo (95%CI: 6.5-7.3), and the overall survival rate at 12 mo was 82.4%. Patients with documented tumor response showed a better PFS than those with disease stabilization or progression [8.5 mo (95%CI: 5.5-11.5) and 4.5 mo (95%CI: 2.5-6.6), respectively; P = 0.042]. Regarding the safety analysis, two-thirds of patients reported at least one treatment-related adverse event, and 25% presented grade 3 toxicities. Of note, no patient experienced grade 4 adverse events. CONCLUSION: TPEx was an adequately tolerated regimen in our population, with low incidence of grade 3-4 adverse events. The median PFS were consistent with those in recent reports of clinical trials evaluating this treatment combination. This regimen may be considered an attractive therapeutic strategy due to its simplified administration, decreased total number of chemotherapy cycles, and treatment tolerability.

[Gastrointestinal stromal tumors. Analysis of 40 cases]. / Tumores del estroma gastrointestinal. Análisis de 40 casos.

Gastrointestinal stromal tumors represent less than 3% of all digestive tumors. They are primarily located in the stomach and the small intestine. The curative treatment is surgical resection. In the case of unresectable tumor or advanced disease, imatinib is the treatment of choice. The purpose of this retrospective study was to describe the characteristics of patients with gastrointestinal stromal tumors treated at our institution in the period 2000-2015. We analyzed 40 consecutive patients diagnosed with gastrointestinal stromal tumor (mean age 58-year old, range 33-84). The mean 5-year survival was 30.5%. At diagnosis, 30 patients had localized disease (75%); 14 of them received adjuvant imatinib and 15 follow-up on observation. In this group the disease-free interval was 55 months. In patients with advanced disease, the progression-free interval was 30 months.

Tumores del estroma gastrointestinal: Análisis de 40 casos / Gastrointestinal stromal tumors. Analysis of 40 cases

Los tumores del estroma gastrointestinal representan menos del 3% de los tumores digestivos. Se localizan principalmente en el estómago y el intestino delgado. El tratamiento radical es la resección quirúrgica. Cuando son inoperables o diseminados la administración de imatinib es el tratamiento de elección. La finalidad de este estudio retrospectivo fue describir las características de los pacientes con tumores del estroma gastrointestinal atendidos en nuestra institución en el período 2000-2015. Fueron analizados los casos de 40 pacientes consecutivos con diagnóstico de tumor del estroma gastrointestinal (edad media 58 años, rango 33-84). La supervivencia media a 5 años del total de pacientes fue 30.5%. Al diagnóstico, 30 (75%) tenían enfermedad localizada; de estos, 14 recibieron imatinib adyuvante y 15 seguimiento en observación. En este grupo, el intervalo libre de enfermedad fue 55 meses. En aquellos con enfermedad diseminada, el intervalo libre de progresión fue 30 meses.

Gastrointestinal stromal tumors represent less than 3% of all digestive tumors. They are primarily located in the stomach and the small intestine. The curative treatment is surgical resection. In the case of unresectable tumor or advanced disease, imatinib is the treatment of choice. The purpose of this retrospective study was to describe the characteristics of patients with gastrointestinal stromal tumors treated at our institution in the period 2000-2015. We analyzed 40 consecutive patients diagnosed with gastrointestinal stromal tumor (mean age 58-year old, range 33-84). The mean 5-year survival was 30.5%. At diagnosis, 30 patients had localized disease (75%); 14 of them received adjuvant imatinib and 15 follow-up on observation. In this group the disease-free interval was 55 months. In patients with advanced disease, the progression-free interval was 30 months.

Delayed union in pediatric forearm fractures.

BACKGROUND: The aim of this study was to assess the predictive factors of delayed union in pediatric forearm fractures. Few previous reports have approached this complication, but contrary to these studies we excluded cases with known pathogenic factors and included in the sample cases treated with conservative methods. METHODS: This is a case-control study of all pediatric shaft forearm fractures presenting delayed union in a minimum follow-up period of 12 months, from 2003 through 2009, in a hospital covering a health area. Exclusion criteria were fracture dislocations, infection, suboptimal osteosynthesis, greenstick, open, pathologic, and associated radial head fractures. Statistical assessment included bivariate and multivariate linear regression analysis. RESULTS: Four hundred and forty-one complete, both-bone forearm fractures were treated during the study period: 14 of them (3.2%) were identified as suffering delayed union; and 63 controls fulfilling inclusion criteria were randomly selected. Bivariate analysis showed significant differences between "union delay" and "control" groups in age, need of surgical treatment, open versus closed reduction, and mean time to hardware removal. However, open reduction of the fracture, more frequent in the "union delay" group, was the only variable that remained associated with time to consolidation in the multivariate analysis. CONCLUSIONS: The strongest predictor of union delay in pediatric forearm fractures is open reduction. Based on our results, we recommend to avoid when possible the open reduction of the fracture in patients undergoing surgery and to use instead closed reduction and internal fixation. LEVEL OF EVIDENCE: A case-control study. Therapeutic level III.

Extensive osteolysis caused by polyethylene particle migration in an anatomical hydroxyapatite-coated hip prosthesis: 10 years' follow-up.

We report our 10-year follow-up results of 630 consecutive Anatomique Benoist Giraud I hip prostheses implanted between June 1990 and December 1995. At this time, 520 were satisfactory and 25 had been revised. Although the majority of patients remained asymptomatic at the end of follow-up, the real survivorship of the implant was less than 91% (33 patients who were in the waiting list for revision due to osteolysis at that time were revised by December 2007). On the other hand, radiographic outcomes were of concern: around 90% of patients showed progressive stress shielding and large granulomatous lesions in the proximal femur, and more than 82% of patients exhibited polyethylene wear in excess of 1 mm (mean=1.69 mm).

A new user-friendly software platform for systematic classification of skin lesions to aid in their diagnosis and prognosis.

BACKGROUND AND AIMS: The field of much less invasive nonablative aesthetic surgery continues to grow, but consistent and truly objective evaluation of the sometimes comparatively small improvements in the treated skin remains a problem for both clinicians and patients. In this work, we present the development of a generic, modular and expandable platform to allow user-friendly image manipulation, sampling extraction and computer-assisted evaluation of tissue features in the dermatological/aesthetic field of clinical medicine. MATERIALS AND METHODS: The unique characteristic of the platform is the modular extension of the algorithm gallery by the use of extended value added services, which enables the easy incorporation of new image processing procedures to customise the gallery for specific concerns. A novel algorithm to evaluate skin wrinkles is also presented as a demonstration of this integration process. The software platform is designed to evaluate image-tissue indices and to identify individual or combined descriptors which will more accurately represent differences in skin quality. It is based on a set of indices correlating clinical expert and computer classifications, which build up a constantly expanding tissue catalogue. By means of this catalogue, the different tissue qualities of photographic samples can be assessed according to the different positions of the samples in the catalogue. CONCLUSIONS: This new platform can be used to generate sensitive and objective comparative measurement not only for diagnostic reports on the pre-treatment condition of samples but also for demonstrating the improvement and efficacy of the prescribed treatment to both the clinician and colleagues and the patient, thereby helping to increase the patient satisfaction index.